KIMBERLY CLARK CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KIMBERLY CLARK CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.08B | Feb 12, 2026 |
| FY2025 | Sep 30, 2025 | $4.15B | Feb 12, 2026 |
| FY2025 | Jun 30, 2025 | $4.16B | Feb 12, 2026 |
| FY2025 | Mar 31, 2025 | $4.05B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.10B | Feb 12, 2026 |
| FY2025 | Sep 30, 2024 | $4.14B | Feb 12, 2026 |
| FY2025 | Jun 30, 2024 | $4.23B | Feb 12, 2026 |
| FY2025 | Mar 31, 2024 | $4.33B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $17.15B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $20.18B | Feb 13, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $18.49B | Feb 7, 2019 |
| FY2018 | Dec 31, 2017 | $18.35B | Feb 7, 2019 |
| FY2018 | Dec 31, 2016 | $18.29B | Feb 7, 2019 |
| FY2017 | Dec 31, 2015 | $18.59B | Feb 8, 2018 |
| FY2016 | Dec 31, 2014 | $19.72B | Feb 8, 2017 |
| FY2015 | Dec 31, 2013 | $19.56B | Feb 11, 2016 |
| FY2014 | Dec 31, 2012 | $19.47B | Feb 18, 2015 |
| FY2011 | Dec 31, 2011 | $5.18B | Feb 29, 2012 |
| FY2011 | Sep 30, 2011 | $5.38B | Feb 29, 2012 |
| FY2011 | Jun 30, 2011 | $5.26B | Feb 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47B | Feb 12, 2026 |
| FY2025 | Sep 30, 2025 | $1.49B | Feb 12, 2026 |
| FY2025 | Jun 30, 2025 | $1.46B | Feb 12, 2026 |
| FY2025 | Mar 31, 2025 | $1.51B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.45B | Feb 12, 2026 |
| FY2025 | Sep 30, 2024 | $1.56B | Feb 12, 2026 |
| FY2025 | Jun 30, 2024 | $1.59B | Feb 12, 2026 |
| FY2025 | Mar 31, 2024 | $1.69B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $6.27B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $6.22B | Feb 13, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $499.00M | Feb 12, 2026 |
| FY2025 | Sep 30, 2025 | $446.00M | Feb 12, 2026 |
| FY2025 | Jun 30, 2025 | $509.00M | Feb 12, 2026 |
| FY2025 | Mar 31, 2025 | $567.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $447.00M | Feb 12, 2026 |
| FY2025 | Sep 30, 2024 | $907.00M | Feb 12, 2026 |
| FY2025 | Jun 30, 2024 | $544.00M | Feb 12, 2026 |
| FY2025 | Mar 31, 2024 | $647.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.76B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.93B | Feb 13, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.35B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.70B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.93B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.68B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $2.56B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $3.24B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $2.99B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $2.23B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $3.36B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $3.38B | Feb 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $326.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $328.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $303.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $292.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $269.00M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $276.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $284.00M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $317.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $309.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $326.00M | Feb 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.78B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.23B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $3.54B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.73B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $2.73B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $3.73B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $2.74B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $2.97B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $2.93B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $3.23B | Feb 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.10B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $16.55B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $17.34B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $17.97B | Feb 8, 2024 |
| FY2023 | Dec 31, 2021 | $17.84B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $17.52B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $15.28B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $14.52B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $15.15B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $14.60B | Feb 7, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $840.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $915.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $547.00M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $514.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $626.00M | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | ($33.00M) | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | ($287.00M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $629.00M | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | ($102.00M) | Feb 8, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.84B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.80B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.89B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.07B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.84B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.90B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $1.47B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $1.47B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $1.58B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.48B | Feb 7, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.61B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $9.26B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $8.37B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $8.20B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $7.86B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $7.57B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $6.69B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $5.95B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $5.77B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $5.83B | Feb 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $688.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.09B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $427.00M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $270.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $303.00M | Feb 10, 2022 |
| FY2021 | Dec 31, 2019 | $442.00M | Feb 10, 2022 |
| FY2021 | Dec 31, 2018 | $539.00M | Feb 10, 2022 |
| FY2020 | Dec 31, 2017 | $616.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2016 | $923.00M | Feb 13, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $7.40B | Feb 8, 2017 |
| FY2016 | Dec 31, 2015 | $6.70B | Feb 8, 2017 |
| FY2015 | Dec 31, 2014 | $6.18B | Feb 11, 2016 |
| FY2014 | Dec 31, 2013 | $5.70B | Feb 18, 2015 |
| FY2013 | Dec 31, 2012 | $5.83B | Feb 14, 2014 |
| FY2012 | Dec 31, 2011 | $6.05B | Feb 22, 2013 |
| FY2011 | Dec 31, 2010 | $5.39B | Feb 29, 2012 |
| FY2010 | Dec 31, 2009 | $5.30B | Feb 23, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Mar 31, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Sep 30, 2024 | 2 | Feb 12, 2026 |
| FY2025 | Jun 30, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Mar 31, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 13, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Mar 31, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Sep 30, 2024 | 2 | Feb 12, 2026 |
| FY2025 | Jun 30, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Mar 31, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 13, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 331.90M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 331.80M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 337.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 337.50M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 336.80M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 338.70M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | 341.40M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | 345.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | 351.10M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | 356.60M | Feb 7, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.63B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.59B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.56B | Feb 13, 2025 |